Sagimet Biosciences Series A Stock Forecast
NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SGMT analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$27.91+212.89%
- Strong buy 2
- Buy 9
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Sagimet Biosciences Series A (2026-10-08), 11 rate the stock a buy or strong buy, 0 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $27.91, with a high estimate of $56.00 and a low estimate of $7.00. The average target implies upside of 212.9% from the current price of $8.92.
The spread between the highest and lowest targets is 700.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SGMT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 17% |
| Buy | 9 | 75% |
| Hold | 0 | 0% |
| Sell | 1 | 8% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | -21.52% |
| Average target | $27.91 | +212.89% |
| High target | $56.00 | +527.80% |